Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1F | P30939 | 11/20 | 0.59 |
| ▸ | HTR1D | P28221 | 5/20 | 0.54 |
| ▸ | HTR1B | P28222 | 4/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR1E | P28566 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30909021 | 1.00 | HTR1F (0.59) | HTR1FHTR1DHTR1BSLC6A4DRD2 | |
| SCHEMBL7005987 | 0.83 | HTR1F (0.57) | HTR1FHTR1DHTR1BSLC6A4ADRA1D | |
| SCHEMBL30908780 | 0.83 | HTR1F (0.57) | HTR1FHTR1DHTR1BSLC6A4ADRA1D | |
| SCHEMBL7015495 | 0.82 | HTR1F (0.72) | HTR1FHTR1DHTR1BSLC6A4DRD2 | |
| SCHEMBL7011040 | 0.78 | HTR1F (0.57) | HTR1FHTR1DHTR1BSLC6A4DRD2 | |
| SCHEMBL30909195 | 0.78 | HTR1F (0.55) | HTR1FHTR1DHTR1BSLC6A4ADRA1D | |
| SCHEMBL7009821 | 0.77 | HTR1F (0.75) | HTR1FHTR1DHTR1BSLC6A4DRD2 | |
| SCHEMBL14280709 | 0.75 | ADRA1D (0.80) | SLC6A4ADRA1D | |
| SCHEMBL7013589 | 0.75 | HTR1F (0.80) | HTR1FHTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL7014539 | 0.75 | HTR1F (1.00) | HTR1FHTR1DHTR1BDRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ LP (CA) | 2026-05-07 | — | — | US | disclosed |
| WO-2024073845-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ, LIMITED PARTNERSHIP (CA) | 2024-04-11 | — | — | WO | disclosed |
| EP-0916670-B1 | Pyrrolo-(3,2-b) pyridines and their use as 5-HT1F agonists | LILLY CO ELI (US) | 2003-05-14 | — | — | EP | disclosed |
| CN-1284874-A | 5-HT1F agonists | LILLY CO ELI (US) | 2001-02-21 | — | — | CN | disclosed |
| EP-0916670-A2 | Pyrrolo-(3,2-b) pyridines and their use as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 1999-05-19 | — | — | EP | disclosed |
| US-5905084-A | 5-SUBSTITUTED-3-(PIPERIDIN-4-YL)- AND -3-(1,2,3,6-TETRAHYDROPYRIDIN-4-YL)PYRROLO(3,2-B)PYRIDINES; SIDE EFFECT REDUCTION; NERVOUS SYTEM AND PSYCHOLOGICAL DISORDERS | ELI LILLY AND COMPANY (US) | 1999-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | HTR1F, HTR1A, HTR1D | HTR1F 1/4885HTR1D 3/4885HTR1B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.